Bluejay Therapeutics announced that its lead product candidate brelovitug (also known as BJT-778) has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD). There are currently no approved treatments for chronic hepatitis D in the United States and most countries around the world.
"Chronic hepatitis delta is the most aggressive form of viral hepatitis and the lack of approved treatments in the United States creates a major unmet need for patients," said Keting Chu, M.D., Ph.D., Founder and Chief Executive Officer of Bluejay Therapeutics. "Breakthrough Therapy designation recognizes the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial as soon as possible to meet our goal of improving patients’ lives."
FDA Breakthrough Therapy designation is intended to expedite the development and regulatory reviews of investigational therapies for serious conditions that demonstrate promising preliminary clinical evidence and potential improvement over existing therapies.
Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!